Health1 min read

STAT+: Zolgensma tumor cases show risks of a common gene therapy tool

By · Via STAT Health · Published by Everything Blog

In short

Adeno-associated viruses have delivered functional genes to thousands of patients, but their potential to trigger tumors has divided the scientific community for two decades. Recent tumor cases linked directly to the gene therapy Zolgensma now provide concrete proof of this carcinogenic risk. According to University of Rochester neurologist Sam Mackenzie, these findings will alter treatment decisions for individuals with spinal muscular atrophy. Moving forward, investigators aim to apply this knowledge to engineer safer gene therapy vectors.

Key points

  • Recent tumor cases tied to Zolgensma provide strong evidence that adeno-associated viruse…: Recent tumor cases tied to Zolgensma provide strong evidence that adeno-associated viruses can cause cancer in patients.
  • Families and physicians must now directly balance the proven oncogenic dangers of these v…: Families and physicians must now directly balance the proven oncogenic dangers of these vectors against their life-saving benefits.
  • Scientists plan to use the new safety findings to guide the future design of less hazardo…: Scientists plan to use the new safety findings to guide the future design of less hazardous gene therapies.

Sources checked by our analysis pipeline: 1

For two decades, researchers debated whether adeno-associated viruses (AAVs), the small viruses used to deliver new genes into thousands of patients, could in certain cases drive tumors. That debate is over.

A series of cases this year has presented powerful evidence that AAVs can cause cancer, forcing researchers and families to weigh the newly confirmed risk against the technology’s life-saving potential — and hopefully determine how to design better therapies in the future.

“It will change the calculus for some patients,” said Sam Mackenzie, a neurologist at University of Rochester, speaking specifically about spinal muscular atrophy patients.

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Health